Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.

Hage C, Hoves S, Ashoff M, Schandl V, Hört S, Rieder N, Heichinger C, Berrera M, Ries CH, Kiessling F, Pöschinger T.

PLoS One. 2019 Jul 10;14(7):e0219517. doi: 10.1371/journal.pone.0219517. eCollection 2019.

2.

Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.

Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Pöschinger T, Kiessling F, Ries CH.

Hepatology. 2019 Oct;70(4):1280-1297. doi: 10.1002/hep.30666. Epub 2019 May 21.

PMID:
31002440
3.

Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses.

Cubas R, Moskalenko M, Cheung J, Yang M, McNamara E, Xiong H, Hoves S, Ries CH, Kim J, Gould S.

J Immunol. 2018 Oct 15;201(8):2273-2286. doi: 10.4049/jimmunol.1800275. Epub 2018 Sep 12.

4.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

5.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.

6.

A drug development perspective on targeting tumor-associated myeloid cells.

Majety M, Runza V, Lehmann C, Hoves S, Ries CH.

FEBS J. 2018 Feb;285(4):763-776. doi: 10.1111/febs.14277. Epub 2017 Oct 19. Review.

7.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

8.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

9.

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.

Baer C, Squadrito ML, Laoui D, Thompson D, Hansen SK, Kiialainen A, Hoves S, Ries CH, Ooi CH, De Palma M.

Nat Cell Biol. 2016 Jul;18(7):790-802. doi: 10.1038/ncb3371. Epub 2016 Jun 13.

PMID:
27295554
10.

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.

Ries CH, Hoves S, Cannarile MA, Rüttinger D.

Curr Opin Pharmacol. 2015 Aug;23:45-51. doi: 10.1016/j.coph.2015.05.008. Epub 2015 Jun 4. Review.

PMID:
26051995
11.

Targeting tumor-associated macrophages in cancer therapy and understanding their complexity.

Cannarile MA, Ries CH, Hoves S, Rüttinger D.

Oncoimmunology. 2014 Dec 13;3(9):e955356. eCollection 2014 Oct.

12.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

13.

Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.

Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, Noerenberg D, Anders HJ, Mayr D, Poeck H, Hartmann G, Endres S, Schnurr M.

Cancer Res. 2013 Mar 15;73(6):1709-20. doi: 10.1158/0008-5472.CAN-11-3850. Epub 2013 Jan 21.

14.

A novel role for granzymes in anti-tumor immunity.

Hoves S, Sutton VR, Trapani JA.

Oncoimmunology. 2012 Mar 1;1(2):219-221.

15.

Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry.

Zhu W, Stevens AP, Dettmer K, Gottfried E, Hoves S, Kreutz M, Holler E, Canelas AB, Kema I, Oefner PJ.

Anal Bioanal Chem. 2011 Dec;401(10):3249-61. doi: 10.1007/s00216-011-5436-y. Epub 2011 Oct 8.

PMID:
21983980
16.

A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells.

Hoves S, Sutton VR, Haynes NM, Hawkins ED, Fernández Ruiz D, Baschuk N, Sedelies KA, Schnurr M, Stagg J, Andrews DM, Villadangos JA, Trapani JA.

J Immunol. 2011 Aug 1;187(3):1166-75. doi: 10.4049/jimmunol.1001670. Epub 2011 Jun 27.

17.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.

18.

Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.

Schütz C, Hoves S, Halbritter D, Zhang HG, Mountz JD, Fleck M.

Immunology. 2011 May;133(1):115-22. doi: 10.1111/j.1365-2567.2011.03417.x. Epub 2011 Feb 22.

19.

Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L.

Konjar S, Sutton VR, Hoves S, Repnik U, Yagita H, Reinheckel T, Peters C, Turk V, Turk B, Trapani JA, Kopitar-Jerala N.

Immunology. 2010 Oct;131(2):257-67. doi: 10.1111/j.1365-2567.2010.03299.x.

20.

Presentation of tumour antigens by dendritic cells and challenges faced.

Robson NC, Hoves S, Maraskovsky E, Schnurr M.

Curr Opin Immunol. 2010 Feb;22(1):137-44. doi: 10.1016/j.coi.2010.01.002. Epub 2010 Jan 29.

PMID:
20116984
21.

The battlefield of perforin/granzyme cell death pathways.

Hoves S, Trapani JA, Voskoboinik I.

J Leukoc Biol. 2010 Feb;87(2):237-43. doi: 10.1189/jlb.0909608. Epub 2009 Nov 13. Review.

PMID:
19915166
22.

A new flow cytometric assay for the simultaneous analysis of antigen-specific elimination of T cells in heterogeneous T cell populations.

Schütz C, Fischer K, Völkl S, Hoves S, Halbritter D, Mackensen A, Fleck M.

J Immunol Methods. 2009 May 31;344(2):98-108. doi: 10.1016/j.jim.2009.03.008. Epub 2009 Mar 28.

PMID:
19332073
23.

In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray.

Hoves S, Aigner M, Pfeiffer C, Laumer M, Obermann EC, Mackensen A.

Leukemia. 2009 May;23(5):877-85. doi: 10.1038/leu.2008.391. Epub 2009 Jan 15.

PMID:
19148137
24.

Inhibitory effect of tumor cell-derived lactic acid on human T cells.

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M.

Blood. 2007 May 1;109(9):3812-9. Epub 2007 Jan 25.

PMID:
17255361
25.

Monocyte-derived human macrophages mediate anergy in allogeneic T cells and induce regulatory T cells.

Hoves S, Krause SW, Schütz C, Halbritter D, Schölmerich J, Herfarth H, Fleck M.

J Immunol. 2006 Aug 15;177(4):2691-8.

26.

Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.

Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, Kreutz M.

Blood. 2006 Mar 1;107(5):2013-21. Epub 2005 Nov 8.

PMID:
16278308
27.

Effects of social stress on blood leukocyte distribution: the role of alpha- and beta-adrenergic mechanisms.

Engler H, Dawils L, Hoves S, Kurth S, Stevenson JR, Schauenstein K, Stefanski V.

J Neuroimmunol. 2004 Nov;156(1-2):153-62.

PMID:
15465606
28.

Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells.

Hoves S, Krause SW, Herfarth H, Halbritter D, Zhang HG, Mountz JD, Schölmerich J, Fleck M.

Immunobiology. 2004;208(5):463-75.

PMID:
15124861
29.

The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis.

Hoves S, Krause SW, Schölmerich J, Fleck M.

Methods. 2003 Oct;31(2):127-34.

PMID:
12957570
30.

Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.

Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Schölmerich J, Fleck M.

J Immunol. 2003 Jun 1;170(11):5406-13.

31.

Decreased T cell stimulatory capacity of monocyte-derived human macrophages following herpes simplex virus type 1 infection.

Hoves S, Niller HH, Krause SW, Straub R, Glück T, Mountz JD, Schölmerich J, Fleck M.

Scand J Immunol. 2001 Jul-Aug;54(1-2):93-9.

Supplemental Content

Support Center